217
6. The absorption measurements were recorded at room temperature and after 10-min incubation time.
7. Do not heat; water temperature should be kept between 15
and 20 °C.
8. The cell concentration that is plated may vary for different cell
lines. For SW480 and HeLa cell lines, we use concentrations
in the range of 500 to 2000 cells/well, respectively.
9. For more reliable results the experiment should be done in
triplicate and in duplicate in case of primary cells and when a
range of drug concentrations are being tested.
10. Drugs should be added into the 96-well plates and stored at
−20 °C in advance of the experiments.
11. Shake the plates for 5 min on a plate shaker by slowly increasing the shaking speed to a maximum of 900 shakes/min. Then
incubate the plate for another 4–6 h at 37 °C in a CO 2 incubator, depending on the cell type.
12. The cell plate has to rest for 10 min before measuring.
13. The percentage of living cells can be determined: The average
optical density of the blank control wells (without cells and if
the drug has no specific optical density without drug as well)
is subtracted from the average optical density of the control
wells (cells but no drugs) and the wells containing the drugs.
Acknowledgments
This work has been co-financed by the European Union and Greek
national funds through the program “Support for Researchers
with Emphasis on Young Researchers” (call code: EDBM34, ΚΕ
14995) and under the research title “Preparation and study of
innovative forms of administration of pharmaceutical molecules
targeting at improved pharmacological properties.”
References
1. World Health Organization (2018) World
health statistics 2018: monitoring health for
the SDGs, sustainable development goals.
World Health Organization, Geneva
2. Barber RM, Fullman N, Sorensen RJD, Bollyky
T, McKee M, Nolte E, Abajobir EA et al
(2017) Healthcare Access and Quality Index
based on mortality from causes amenable to
personal health care in 195 countries and territories, 1990–2015: a novel analysis from the
Global Burden of Disease Study 2015. Lancet
390(10091):231–266
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit
R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F (2012) GLOBOCAN 2012:
estimated cancer incidence, mortality and
prevalence worldwide in 2012. Int J Cancer
136:E359–E386
4. Plummer M, de Martel C, Vignat J, Ferlay J,
Bray F, Franceschi S (2016) Global burden
of cancers attributable to infections in 2012:
a synthetic analysis. Lancet Glob Health
4(9):e609–e616
Antitumor Efficacy of Ceranib-2 with Nano-Formulation of PEG and Rosin Esters
6. The absorption measurements were recorded at room temperature and after 10-min incubation time.
7. Do not heat; water temperature should be kept between 15
and 20 °C.
8. The cell concentration that is plated may vary for different cell
lines. For SW480 and HeLa cell lines, we use concentrations
in the range of 500 to 2000 cells/well, respectively.
9. For more reliable results the experiment should be done in
triplicate and in duplicate in case of primary cells and when a
range of drug concentrations are being tested.
10. Drugs should be added into the 96-well plates and stored at
−20 °C in advance of the experiments.
11. Shake the plates for 5 min on a plate shaker by slowly increasing the shaking speed to a maximum of 900 shakes/min. Then
incubate the plate for another 4–6 h at 37 °C in a CO 2 incubator, depending on the cell type.
12. The cell plate has to rest for 10 min before measuring.
13. The percentage of living cells can be determined: The average
optical density of the blank control wells (without cells and if
the drug has no specific optical density without drug as well)
is subtracted from the average optical density of the control
wells (cells but no drugs) and the wells containing the drugs.
Acknowledgments
This work has been co-financed by the European Union and Greek
national funds through the program “Support for Researchers
with Emphasis on Young Researchers” (call code: EDBM34, ΚΕ
14995) and under the research title “Preparation and study of
innovative forms of administration of pharmaceutical molecules
targeting at improved pharmacological properties.”
References
1. World Health Organization (2018) World
health statistics 2018: monitoring health for
the SDGs, sustainable development goals.
World Health Organization, Geneva
2. Barber RM, Fullman N, Sorensen RJD, Bollyky
T, McKee M, Nolte E, Abajobir EA et al
(2017) Healthcare Access and Quality Index
based on mortality from causes amenable to
personal health care in 195 countries and territories, 1990–2015: a novel analysis from the
Global Burden of Disease Study 2015. Lancet
390(10091):231–266
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit
R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F (2012) GLOBOCAN 2012:
estimated cancer incidence, mortality and
prevalence worldwide in 2012. Int J Cancer
136:E359–E386
4. Plummer M, de Martel C, Vignat J, Ferlay J,
Bray F, Franceschi S (2016) Global burden
of cancers attributable to infections in 2012:
a synthetic analysis. Lancet Glob Health
4(9):e609–e616
Antitumor Efficacy of Ceranib-2 with Nano-Formulation of PEG and Rosin Esters